地诺单抗治疗骨转移的疗效好吗？

Is (Denosumab) effective in treating bone metastases? Denosumab is the first approved monoclonal antibody that specifically targets RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. Human RANKL mRNA is mainly found in bones, bone marrow and lymphoid tissues. Its main function in bones is to stimulate the differentiation and activity of osteoclasts and inhibit the apoptosis of osteoclasts. Osteoclasts are responsible for bone resorption, and osteoclast precursors must have low levels of macrophage colony-stimulating factor and RANKL during their differentiation into mature osteoclasts. Denosumab (Denosumab) has a high affinity for RANKL, preventing RANK ligands from activating RANK on the surface of osteoclasts, inhibiting osteoclast activation and development, reducing bone resorption, increasing bone density and bone strength of both cortical bone and trabecular bone, promoting bone reconstruction, and reducing the incidence of vertebral, non-vertebral and hip fractures in postmenopausal osteoporotic women.

Data from a phase 3 trial show that patients treated with denosumab had greater increases in bone density than those treated with risedronate. The study compared denosumab 60 mg subcutaneously every six months with risedronate 5 mg once daily in two subgroups, those who continued glucocorticoid therapy and those who started glucocorticoid therapy.

The data showed that, in the subgroup of patients who received continuous glucocorticoid therapy, denosumab resulted in greater increases in BMD compared with risedronate, with increases in bone density occurring at both the lumbar spine (4.4% and 2.3%, respectively) and the hip (2.1% and 0.6%, respectively). In the subgroup of patients who had recently started glucocorticoid therapy, denosumab also induced greater BMD gains, also in the lumbar spine (3.8% vs. 0.8%, respectively) and hip joint (1.7% vs. 0.2%, respectively).

The above is the clinical effect of denosumab (Denosumab) in the treatment of bone metastasis provided by our Medical Companions Overseas Medical Consulting Service Company. From this point of view, the effect of (Denosumab) is still very good.

Recommended related hot articles: /newsDetail/74130.html